PRF Technologies (PRFX) Net Income towards Common Stockholders Growth (1y) (2021 - 2024)
PRF Technologies (PRFX) Net Income towards Common Stockholders Growth (1y) (2021 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | PRF Technologies | 654,452.72 | -3.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -204.12% |
| Mar 31, 2024 | -118.64% |
| Dec 31, 2023 | -21.01% |
| Sep 30, 2023 | 31.46% |
| Jun 30, 2023 | -19.97% |
| Mar 31, 2023 | -39.47% |
| Dec 31, 2022 | -28.75% |
| Sep 30, 2022 | -17.03% |
| Jun 30, 2022 | -10.80% |
| Mar 31, 2022 | 6.52% |
| Dec 31, 2021 | -65.42% |
| Sep 30, 2021 | -185.14% |
| Jun 30, 2021 | -94.01% |
| Mar 31, 2021 | -28.28% |